Published in Women's Health Weekly, December 9th, 2004
"Third quarter results at our Novogyne joint venture reflect our continued leadership position in the transdermal hormone therapy ("HT") market," said Robert C. Strauss, Noven president, CEO and chairman.
Noven's net revenues for the quarter ended September 30, 2004 were $10.1 million, an 11% increase over the $9.1 million reported in the quarter ended September 30, 2003. Net revenues for the 2003 quarter reflected the establishment of a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly